Clinical Trial Update: Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sunitinib as second-line treatment for advanced biliary tract cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Advanced Biliary Tract Adenocarcinoma | Phase 2 | Status: COMPLETED